1. Introduction

Peripheral nerve injury, sometimes referred to as acquired nerve injury, is a catastrophic injury that imposes a number of negative outcomes that usually inflict one or more adverse health conditions or disabilities on its victims. These adverse health conditions and disabilities frequently place both short-term and long-term burdens on individuals, families, communities, the workplace, the health care system and economies in general. Considerable money and effort have been expended on attempts to lessen, prevent or ameliorate the effects of trauma on peripheral nerves.

There are many outcomes of neuropathy of peripheral nerves. Neuropathic pain is perhaps the best documented, largely because of the enormous impact of chronic neuropathic pain on individuals and the fact that it tends to be refractory to medical treatment [1, 2]. However, other outcomes of secondary injury to peripheral nerves include, in terms of sensory disturbance, numbness, dysesthesia (an unpleasant abnormal sensation, whether spontaneous or evoked), paresthesia (an abnormal sensation, such as tingling, whether spontaneous or evoked), hypoesthesia (decreased sensitivity to stimulation, excluding the special senses) and loss of proprioception (possibly contributing to altered gait and to falls). In terms of motor control, peripheral neuropathy can lead to weakness, loss of movement, loss of corrective motor control and loss of muscle mass. Neuropathy of the autonomic nervous system can be manifest as orthostatic hypotension, dysautonomia, altered sudomotor function, and the like. Injury or damage to nerves or nerve cells can be the result of factors or events that are unanticipated or unexpected, such as an accident, while other factors or events can be anticipated, such as a result of chemotherapy or even surgical intervention.

It is the thesis of the present overview that many of the negative outcomes and disabilities of peripheral nerve injury can be reduced in severity, or prevented altogether, by early interven-
tion with the appropriate methods, procedures and pharmaceutical formulations, continued for a medically-beneficial period of time.

While there are currently practices and interventions to treat, manage or diminish the negative outcomes of peripheral nerve injury once they have been established, immediate or early preventive approaches targeted at the development phase of these outcomes are nonexistent, few or ineffective. That is, at the time of a traumatic event medical attention focuses on treatment of immediate symptoms such as bleeding or to avoid infection, but medical attention does not typically address treatment to prevent the cascade of restorative, or adaptive, and degenerative, or maladaptive, metabolic and biochemical processes that result from peripheral nerve injury and that lead to prolonged or permanent adverse health conditions and disability.

Peripheral nerve injury or damage is not only to nerves or nerve cells, but can include damage to neural support cells, such as satellite cells and myelin cells, and also local circulation. In the context of the present overview the term "neural support cell" is any cell that supports or could be considered to support the health, normal function and survival of nerves and nerve cells, and include myelin cells and satellite cells, astroglia, oligodendrocytes, Schwann cells, vascular endothelial cells, and the like. Further, the term "neural support tissue" is any tissue that supports or could be considered to support the health, normal function, phenotype, gene expression or survival of nerves, nerve cells or support cells, and include the vasculature or microvasculature, particularly the endothelial cells that prevent blood from leaking into peripheral nerve tissue and that provide the selective blood-nerve barrier that allows the passage of certain supportive chemicals into nerve tissue as well as the passage of nerve tissue wastes out of nerve tissue.

Degeneration of axons or of neural support cells triggers a cascade of activated chemical pathways that lead to injury to otherwise intact nerve cells, Schwann cells, local vasculature and even more remote nerve cells by entry of degradation products into the blood circulation.

Trauma can be of many different types. For example, physical trauma can occur in vehicle accidents, in workplace accidents, sports accidents, on the battlefield, from falls, from assaults, from landmines and from explosive or other blasts, and the like, but can also occur as a result of surgical or other medical procedures.

Chemical trauma to nerves or nerve cells or neural support cells or neural support tissues can occur, from alcohol overdose, drug abuse, stimulant drugs such as pentylenetetrazol, carbon dioxide poisoning, acrylamide and related chemicals, overexposure to certain environmental chemicals such as copper or natural hazards such as scorpion venom toxin, herbicides, agricultural insecticides such as lindane, many industrial chemicals, neurotoxin bioterrorism chemicals such as soman and sarin, as well as radiation bioterrorism chemicals such as polonium and strontium.

Medically-induced trauma to nerves or nerve cells or neural support cells or neural support tissues can occur as a result of surgery, amputation, injections, laparoscopy, implants, during a medical procedure that reduces or impedes the blood supply to any tissue containing nerve cells for any period of time as described herein, chemotherapy (for example from methotrexate,
cisplatin, cytosine arabinose, carmustine, thiotepa among others), radiation therapy, immu-
nosuppressants (such as tacrolimus).

Surgery in and of itself can produce other types of trauma that are injurious to nerves, nerve
cells and nerve support cells and neural support tissues. For example, the life-saving benefits
of cardiac surgery are frequently followed by manifestations of damage to peripheral nerves
and chronic neuropathic pain, which remains a significant complication of cardiac surgery and
occurs with an incidence of 15% [3]. In a ten-year overview it was reported that chronic post-
surgical pain constitutes a significant medical need that may be amenable to be reduced or
prevented [4]. The incidence of persisting pain following amputation is 50-85%, that of
intrathoracic surgery is 30-55%, mastectomy is 20-50%. Persisting pain after even simple
procedures such as hernia repair and cholecystectomy are reported to be 5-35% and 5-50%,
respectively. Post-sternectomy pain has been reported to be as high as 28% [5], hysterectomy
as high as 32% [6], caesarean section as high as 12-18% [7, 8]. These are all astounding numbers,
especially given the position taken here that the persisting pain may be reduced or prevented
by appropriate and timely pharmaceutical intervention.

Similarly to medical surgical procedures, the incidence of peripheral nerve injury resulting
from medical chemotherapy procedures has been underappreciated. A recent systematic
review [9] has calculated that the prevalence of patients with neuropathic pain as a result of
chemotherapy varies between 19% and 39%. Neuropathology-inducing chemotherapy drugs
include paclitaxel, bortezomib, ixabepilone and oxaliplatin, as examples.

Broader than chemotherapy, peripheral neuropathy resulting from medications and toxic
chemicals may also be preventable. Drugs that can trigger peripheral neuropathy include some
antibiotics, as well as drugs for other disorders, including infliximab, etanercept, leflunomide,
linezolid, statins, dichloroacetate and others [10-12]. A number of industrial chemicals also
have the potential to induce peripheral neuropathy [12, 13]. Based on available knowledge,
these types of peripheral neuropathy can be reduced or prevented if the appropriate medical
intervention is applied early.

2. Secondary injury resulting from peripheral nerve trauma

Peripheral nerve injury generally consists of two related processes, the initial injury and a
secondary injury [14] that results from cascades of self-propagating metabolic and biochemical
processes that lead to loss of cell function and cell death. Disability occurs to a large extent
from the secondary injury that is triggered by the primary injury. Whether the numbers are
large, as in the case of battlefield peripheral nerve injury, or small, as with falls in the elderly,
peripheral nerve injury can be devastating to the individual. Whether the numbers are large,
as those resulting from car accidents, or small, such as those resulting from laparoscopic
surgery, the result of peripheral nerve injury can be a future of constant burning, debilitating
neuropathic pain and other adverse health conditions.

In the context of the present overview the term "secondary injury" or "secondary damage",
terms that can be used interchangeably for the present context, means any damage, injury,
harm, loss, change in structure, change in phenotype, change in gene expression or change in function or survival of nerves, nerve cells, neural support cells or neural support tissue that occurs after a traumatic event and develops over the seconds, minutes, hours, days, weeks or even months following such an event. Secondary injury or secondary damage is usually considered to result from consecutive or parallel biochemical cascades of cellular and metabolic processes that are activated or triggered by the trauma-induced direct tissue damage to a peripheral nerve. Secondary injury or secondary damage is usually considered to involve endogenous processes or biosynthetic pathways that govern, regulate or influence the structure, health, function, gene expression or survival of nerves or nerve cells, or cells or tissues upon which nerves or nerve cells depend to maintain health and function, such as neural support cells and neural support tissues often with delayed clinical presentation [14]. Whereas a primary injury is irreversible [15], this secondary injury is salvageable [14]. This secondary injury is a neuropathology that can be reduced or prevented by appropriate and timely intervention.

3. Functional outcomes of peripheral nerve injury

Neuropathic pain is defined as pain caused by damage, lesion, disease or altered function of the peripheral somatosensory nervous system and is characterized as a constant burning pain accompanied by hyperesthesia (increased sensitivity to stimulation, excluding the special senses). Hyperesthesia is usually clarified in clinical use as either hyperalgesia (increased pain from a stimulus that normally provokes pain) or allodynia (pain due to a stimulus that does not normally provoke pain). Neuropathic pain may also include periodic attacks of pain that feel like electric shocks or shooting pain.

In understanding mechanisms of peripheral neuropathic pain it is important to distinguish this type of pain from nociceptive pain and inflammatory pain. Nociceptive pain is pain that arises from actual or potential damage to non-neural tissue and is due to the activation of nociceptors in these tissues. Nociceptive pain functions to protect from potential tissue damage or from further tissue damage, and triggers physiological and behavioural reflexes to avert damage. Inflammatory pain is pain that is triggered by inflammation and serves to aid in healing and repair of injured non-neural tissue. Each of nociceptive and inflammatory pain is brought about by a specific set of mechanisms and each has a specific treatment algorithm. Neuropathic pain is different, not only with respect to underlying mechanisms and treatments [16], but it is considered to be a maladaptive pain, as this type of pain neither protects nor supports healing and repair.

4. Processes and mechanisms leading to peripheral neuropathology following peripheral nerve trauma

Trauma to a peripheral nerve has effects on sensory neurons, on motor neurons controlling skeletal muscle and on autonomic efferent neurons controlling the cardiovascular system and
organs. This accounts for the range of outcomes of peripheral nerve trauma indicated above. As much of the research in this area is focussed on symptoms, available knowledge tends to be clearly fractionated into the bases of sensory loss, motor loss or autonomic dysfunction.

The overriding research on sensory loss pertains to peripheral neuropathic pain, which will be surveyed here to exemplify the pathophysiological changes that occur in peripheral nerves more generally. Even here, though, much attention is focused on changes in the central nervous system [17], particularly at the level of the first sensory synapse in the spinal cord and in the brain stem [18, 19]. As a result, treatment options tend to focus on targets within the central nervous system [20-22]. Research also tends to focus on the incidence of neuropathic pain rather than on underlying neuropathological processes [18]. Notwithstanding this orientation, the first step here will be to examine the changes in peripheral nerves that result from injury.

Understanding pathophysiology arising from peripheral nerve trauma is further complicated by the various types of trauma, which consist largely of a total cut of a peripheral nerve, a partial cut, an event-triggered compression, a slowly-developing compression (such as from a tumour), and a degeneration of nerve cells or of neural support cells and neural support tissues. Total and partial cuts as well as event-triggered compression can occur as a result of an accident, a violent act or surgery. Degeneration can be induced, for example, by chemotherapy. Physical, surgical and chemical events provide a start time for medical care [4, 12, 23]. As post-herpetic neuralgia is associated with a time-locked event, which is the start of the symptoms of shingles, this type of neuropathic pain is included in this overview [24-26], as would be any other infection-or inflammation-induced neuropathy that is time-locked.

Multiple pathophysiological, neurochemical, and anatomical changes are triggered by peripheral nerve injury, whereby a simple focal peripheral nerve injury unleashes a range of peripheral as well as central nervous system processes that contribute to persistent pain and abnormal sensation. Repair mechanisms of neural tissues in response to injury, and the reaction of adjacent tissues to injury lead to a state of hyperexcitability in primary afferent nociceptors [27], a phenomenon termed peripheral sensitization. In turn, central neurons innervated by such nociceptors undergo dramatic functional changes including a state of hyperexcitability termed central sensitization [28].

Normally these sensitization phenomena extinguish as the tissue heals and inflammation subsides. However, when primary afferent function is altered in an enduring way by injury or disease of the peripheral nerves, these processes persist, become chronic and may be highly resistant to treatment.

Much of what has been learned regarding the pathophysiology of injury causing neuropathic pain has come from animal studies. Human laboratory studies, although limited in number, support the idea that the pathophysiological mechanisms discovered in animal models are valuable and relevant to our understanding of human neuropathic pain [29, 30]. There are several animal models of peripheral neuropathic pain, largely based on the types of primary injury or trauma that lead to peripheral neuropathic pain in humans [31-39].

Effects of peripheral nerve injury in these models include major changes in the properties of nerve cells and their support cells, particularly the Schwann cells. Changes in sensory nerve
cells include spontaneous ectopic action potential generation, persisting sensitization of sensory nerve cell peripheral terminals, and increased release of excitatory neurotransmitters from their central nerve terminals [27, 40-42]. Other changes in sensory nerve cells include a change in function [43], changes in the expression of cell constituents such as sodium channels [44] and changes in the expression of neurotransmitters [45, 46], including de novo expression of substance P in large fibre, non-nociceptive sensory neurons [40]. While there is currently no universally effective treatment for peripheral neuropathic pain, one that is included in the algorithm of treatment regimens is gabapentin [16, 21], which it thought to act by reducing the release of excitatory neurotransmitters from the central terminals of sensory neurons [47, 48]; this action is thought to occur through inhibition of the influx of calcium into the nerve terminals, which is necessary for synaptic release mechanisms [49].

Two major hypotheses have been put forward to explain the role of sensory neurons in the generation of neuropathic pain [27]. One is the classic “excitable nociceptor hypothesis”, which implicates a reduced response threshold in nociceptive small C-fibre sensory neurons. Another hypothesis suggests ectopic impulse activity is generated in low threshold mechanoreceptor large fibre Aβ sensory neurons and that this activity is abnormally “amplified” in the spinal cord by central sensitization [27, 50]. The hypothesis implicating C-fibre sensory neurons in causing neuropathic pain is mainly based on the abnormal spontaneous activity observed in these neurons. However, several studies have shown that large fibre sensory neurons undergo significant changes in their electrophysiological properties as well as other phenotypic changes, such as the expression of substance P [51-53]. Further studies have shown that large fibre Aβ neurons, not the small C-fibre sensory neurons might be the major drivers of stimulus-evoked neuropathic pain and tactile alldynia [54].

Irrespective of these outcomes of peripheral nerve injury, which manifest in established neuropathic pain, the focus of the present overview is on the mechanisms and processes that lead to these outcomes. A consensus is that once these processes are set in place the resulting neuropathic pain is relatively refractory to medical treatment. The present overview therefore addresses the initial changes in peripheral nerve cells, neural support cells and neural support tissues that lead to long-term or permanent pathology, adverse health outcomes or disability.

5. Triggering events and cellular processes leading to adverse outcomes

Specific mechanisms triggered by injury to sensory nerve cells vary depending on the site of the trauma and the type of trauma [55]. There is also a reported difference in the restorative and degenerative processes activated between immature and mature rat models [56].

A cut to an axon induces an immediate influx of calcium, which disrupts the ionic balance of the nerve cell and initiates transport of a number of intracellular and extracellular chemicals to the nerve cell body in the dorsal root ganglion [57], contributing to spontaneous ectopic activity in small diameter normally nociceptive neurons and/or in the large diameter normally non-nociceptive neurons (summarized in [18, 27, 58]). Other changes are also induced in nerve
cell bodies in the dorsal root ganglia when injury occurs to the axons, including chromatolysis, displacement of the cell nucleus, cell shrinkage and a decrease in axonal transport [59].

Abrupt non-cutting trauma can also cause injury to axons, which then begin to degenerate over the next several days [60, 61], leading to cell death in a delayed, progressive process [62]. Degeneration of the central and peripheral terminal projections of the damaged and dying nerve cells leads to sprouting of the terminal projections of neighbouring undamaged nerve cells, constituting a morphological reorganization of the spinal cord neuronal circuitry [63] and perhaps also of the peripheral innervations of tissues.

Trauma to the axon also alters the normal flow of proteins orthogradely toward the cell body in the dorsal root ganglion, and retrogradely toward the peripheral terminal along intracellular filaments. This alters the information arriving to the protein assembly mechanisms in the cell body and this leads to changes gene expression of proteins. Changes in gene expression follow a temporally specific pattern [64], indicating that different cellular contents are produced at varying times following trauma to a peripheral nerve. In addition to changes in the expression of proteins there are also changes in the cellular distribution of these proteins, particularly of sodium and calcium channels [65], which are critically involved in neuronal excitability and conduction. Changes in gene expression and generation of specific proteins are particularly relevant to secondary injury including changes in the expression of neurotransmitters, such as substance P, of trophic factors such as brain-derived neurotrophic factor and other factors, as well as kinases and other degradative enzymes [45, 66].

Changes in expression and distribution of calcium channels have received particular attention. Expression of the α-2-δ subunit of voltage-gated calcium channels is increased in neuropathic pain models and this increase correlates with the onset and duration of pain scores [67]. The anticonvulsant, gabapentin, and its derivative, pregabalin, are both reported to bind to the α-2-δ subunit of voltage-gated calcium channels and inhibit transport of this subunit to nerve terminals [68]. Gabapentin and pregabalin have both shown clinical efficacy for treating chronic neuropathic pain in humans [16, 69, 70].

Changes also occur in Schwann cells. Any changes in the supporting Schwann cells are important to understand because of their pivotal role in sustaining the physiological properties of peripheral nerve cells and because they are involved in a degenerative process termed ‘Wallerian degeneration’ [71]. Schwann cells are the glial cells of the peripheral nervous system, and include myelinating cells and non-myelinating satellite cells. Dysfunction of Schwann cells is at the basis of several peripheral nerve disorders, such as Guillain-Barré disease and Charcot-Marie-Tooth disease [72-74]. As the Schwann cells decompose so do the myelin sheaths. The products of this decomposition trigger proliferation of new undifferentiated Schwann cells that align along the Bungner’s bands that constitute the tubes within which the nerve bundles are contained, along with their support cells. Toll-like receptors are strongly induced by axotomy, they are critically involved in degeneration [75.76] and they lie at the crossroads of peripheral nerve pathology and pain [77].

Changes also occur in other non-neuronal cells, affected by axonal degeneration and Wallerian degeneration of axons. Macrophages and lymphocytes as well as immune cells from the blood infiltrate dorsal root ganglion cells and are attracted to the site of nerve damage [71, 78]. This
chemical milieu contains many components that impact on all cell types, including neurotrophic factors such as brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor and neurotrophin-3 [79-82], pro-and anti-inflammatory cytokines such as tumor necrosis factor (TNF-α), interleukin-1α (IL-1α), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-10 (IL-10) and leukemia inhibitory factor [83, 84] and the chemokine monocyte chemoattractant protein-1 [85]. Axon-promoting chemicals are thought to provide support for regrowing axons [83]. Some components are thought to cause increased excitability of undamaged axons as a cause of neuropathic pain [86]. Even cutting ventral roots has been shown to lead to neuropathic pain behaviour in rats [87], presumably due to the migration of chemicals from degenerating nerve and neural support cells associated with motor control to intact neighbouring sensory neurons [88-90].

Peripheral nerves travel alongside blood vessels and trauma to the nerve often physically disrupts the blood-nerve barrier, allowing the milieu of chemicals produced by axon and Schwann cell degeneration to enter the bloodstream, which then carries these chemicals to remote parts of the body, including direct access to uninjured dorsal root ganglia, the enteric nervous system and the central nervous system [91]. This tends to carry peripheral nerve injury to remote sites beyond the site of a primary injury.

6. Processes and mechanisms of the changes in spinal cord resulting from peripheral nerve injury

Although the focus of the present overview is on peripheral nerve injury, changes in sensory nerve cells produce changes in spinal cord nerve cells, glial cells and other neural support cells, and it is generally held that some of the outcomes of peripheral nerve injury may be brought about as a result of changes in the spinal cord. For example, peripheral nerve injury produces excessive excitation and activation of sensory neurons, which causes excessive release of glutamate, substance P and other neurotransmitters from their central terminals in the spinal cord and brain stem. Besides leading to central sensitization, released neuropeptides regulate gene expression and therefore the phenotype of neurons in the spinal cord and brain stem [92]. Outcomes of peripheral nerve injury in animal models have been reported to include major changes in the properties of spinal neurons and spinal neural support cells and neural support tissues [93-95]. Peripheral nerve injury has also been reported to produce changes in the processing of sensory information at the spinal and supraspinal levels [96-101].

As a result of acute peripheral nerve injury, discharge from both damaged and adjacent intact primary afferent fibres becomes abnormal. This modified afferent drive in turn has been reported to elevate the excitability and discharge of dorsal horn neurons [43, 102] and to induce changes in sensory processing at the level of the spinal dorsal horn including altered calcium-dependent signal transduction mechanisms [103], a shift in anion gradient [104], microglial activation [105], decreased inhibitory mechanisms [58], apoptosis [106] and others. It is thought that this modified sensory processing at the level of the spinal dorsal horn, termed central sensitization [50, 107, 108] or long term potentiation [109], contributes to neuropathic pain by exacerbating excitatory transmission to supraspinal structures.
In view of the evidence that central sensitization in humans is maintained by a constant barrage of synaptic activity from primary afferent nerve cells [58, 110] it is important in understanding mechanisms of neuropathic pain to understand the properties of primary sensory neurons and how they adapt to or change in response to nerve injury. It is at these properties, particularly at the processes that are involved in the initial stages of neuropathology, that early pharmaceutical intervention can be aimed.

7. Standard treatment following peripheral nerve injury

For complete cut of a peripheral nerve a standard procedure is nerve repair or nerve grafting, but this approach remains suboptimal and is usually performed long after the cut has occurred. Axons have the capacity to regrow, but this is often incomplete or the regeneration misses the original tissue target. As a result there has been a wealth of research on mechanisms of regeneration and respective treatment modalities. Yet, outcome generally remains poor.

To make matters worse, leaders in the field of pain have suggested that "there is little evidence that chronic postsurgical pain can be prevented" and they cite papers such as those by Kehlet et al. [23], Gartner et al. [111] and Katz and Seltzer [112]. In fact, this assessment might just be correct, as the concept of ‘prevention’ of postsurgical chronic pain is usually embedded in the concept of peri-surgical anaesthesia [113-115] rather than control of the degenerative processes that lead to secondary injury to nerve cells and Schwann cells in peripheral nerves. This latter approach is not included in steps to prevent postsurgical pain, let alone a rationalized, combination therapy based on a timed sequence of pharmaceutical interventions aimed at reducing or preventing the processes involved in secondary injury to these cells. The consensus therefore teaches away from this rationalized approach toward techniques that have been proven by evidence to be relatively ineffective, condemning multiples of thousands each year to a life of unending refractory pain.

Numerous efforts have been made to develop new and effective drugs and other approaches to treat neuropathic pain. Some treatments have been found to have beneficial effects. These include treatment with multimodal analgesics [116], anticonvulsants [16, 21], botulinum toxin [117, 118], peripheral nerve electrical stimulation [119, 120], as have invasive approaches such as spinal cord stimulation [121] and administration of stem cells [122]. However, these are aimed at treating existing pain. What are not being explored are new treatments to prevent the onset of neuropathic pain or any other of the sensory, motor or autonomic adverse sequelae of peripheral nerve injury.

8. Limitations to incentives to prevent secondary injury to peripheral nerves

Trauma to peripheral nerves is not considered life threatening, whether physical, chemical, metabolic or surgical. As a result there is limited incentive to pursue medical interventions,
methods and procedures to reduce or prevent secondary peripheral nerve injury that results from trauma. For example, there is no appreciation of immediacy in medical intervention. Research on medical intervention for neuropathic pain focuses on treatment of an existing condition, once a complete diagnosis has been made. Complete or correct diagnosis can take weeks, months or even years. Standard treatment following peripheral nerve trauma typically involves drugs that reduce the pain intensity. Thus, in the pursuit of new drugs, neuropathic pain resulting from peripheral nerve trauma is becoming understood in terms of a static, or an established, condition. The processes that are involved in the initial pathophysiology of peripheral nerve injury remain poorly understood and few efforts are being made to understand or to intervene in these processes.

A second limit to incentive to understanding the pathophysiology of peripheral nerves is that a major focus of research has been on the changes in the spinal cord and other central nervous system structures that result from peripheral nerve trauma [123]. As a result, much of the research on the pathophysiology of neurons and neural support cells in neuropathic pain has focused on changes in the spinal cord, where the predominant concepts are 'central sensitization' or 'long-term potentiation' [108, 124] and 'neuroplasticity' [125], as mechanisms underlying the pain. While this is important, it has tended to shift focus away from the changes in peripheral nerves and the role of primary afferent drive in the mechanisms of neuropathic pain [27, 43, 102].

There is a rich literature pertaining to pharmacological treatments for peripheral neuropathic pain as an existing condition, summarized in a number of thorough reviews [16, 20-22, 126]. This abundant literature is largely due to the fact that neuropathic pain is a particularly debilitating type of chronic pain, yet it remains refractory to medical treatment in a large number of patients. Despite this huge medical need, there is little information or drive with regard to reducing or preventing the development of peripheral neuropathic pain, which is the focus of the present overview.

9. New approaches to minimize secondary injury following peripheral nerve injury

Despite abundant information regarding the processes and mechanisms of the changes in the periphery and in the spinal cord, there appears to be little effort being made to understand these processes and mechanisms or to develop new therapeutics to prevent trauma-induced secondary injury in peripheral nerves. Steps to reduce or to prevent the development of neuropathic pain are not generally considered in medical practice, other than steps to avoid traumatic events. Prevention, from a medical intervention standpoint, is not found in consensus statements.

Novel therapies under development retain the focus on treatment of an existing symptom. Steps to reduce or prevent secondary nerve injury following peripheral nerve trauma through immediate medical intervention do not appear in major national statements or reports, such as the US National Pain Care Policy Act of 2009, the 2011 Annual Report of the Chief Medical
Given the enormous impact of trauma-induced peripheral neuropathology and its sequelae on individuals, on families, on the healthcare system and on the economy, and the enormous social impact specifically of abuse of pain-relieving drugs, this presents an opportunity to exploit the limited knowledge we have regarding mechanisms underlying the secondary injury to peripheral nerves following traumatic events, to develop effective medical intervention to reduce or prevent the secondary processes that lead to peripheral nerve pathology.

Some insights into possible therapeutic approaches have come from animal studies, which have shown that peripheral neuropathy resulting from physical trauma is preventable when immediate and appropriate therapy is introduced [127] but is not preventable when treatment is delayed [128-131]. There is limited evidence that immediate or at least early medical intervention may have beneficial effects on long-term outcome. For example, immediate but not prolonged treatment with either an NK-1 receptor antagonist [130] or with progesterone [129] has been shown to have long-term benefit in an animal model of peripheral nerve injury. In fact, a recent study on early treatment with peripheral nerve stimulation of soldiers on the battlefield has reported improved functionality and opioid use reduction [120], a point well made as extremity trauma is a relatively more common medical condition in battle now because of advances in body armour [132].

As described above, due to the plethora of mechanisms that are triggered by event-related trauma to peripheral nerves combinatorial approach to reducing or preventing secondary injury to peripheral nerves may be necessary. There is presently no therapeutic approach to prevent or reduce the adverse health conditions or disability that result from trauma-induced damage to peripheral nerve cells, peripheral neural support cells or peripheral neural support tissues. There is little research directed at translation of new discoveries from animal studies to preventing or reducing peripheral neuropathology in humans and, as a result, until this invention there is little evidence or indication that this medical need will be met.

10. Recommendations for future research.

If new, appropriate therapeutics are to be developed in order to prevent or limit the disability that ensues from peripheral nerve injury, such therapeutics will have to target the biochemical and metabolic processes triggered by trauma, and therefore research is needed to understand these processes beyond what has been described in this overview. Further, from this understanding novel targets need to be identified that offer opportunities to develop novel therapeutics.

Injury triggers cascades of cellular, biochemical and metabolic processes, some of which tend to return nerve cells, neural support cells and neural support tissues toward normal function and cell health. Some changes tend to drive nerve cells, neural support cells and neural support tissues toward loss of cell function or cell death. The former group of processes is considered
to be restorative or adaptive processes. The latter group of processes is considered to be degenerative or maladaptive. The eventual outcome at the cellular and tissue levels is determined by or results from the balance of all the restorative and degenerative processes triggered by or resulting from the primary injury and its sequelae. Indeed, the damage caused by these secondary processes can be as serious and extensive as, or even more serious and extensive than, that caused by the primary trauma. Secondary processes also progress over time so that injury and damage can continue over the days, weeks and even months after the initial injury. Further, the secondary processes can also progress spatially so that injury and damage can spread spatially and manifest at sites remote from the site of the primary trauma to other peripheral nerves.

This balance can be tipped toward normal function and health by appropriate pharmaceutical intervention at the appropriate time. This can be achieved because of the chemical nature or basis of the restorative and degenerative processes occurring at the cellular, biochemical and metabolic levels.

As indicated above, there are many targets or points of entry for pharmaceutical promotion, facilitation or potentiation of restorative processes to tip this balance toward function and health, and there are many targets or points of entry for pharmaceutical inhibition, lessening or blocking of degenerative processes that tip this balance away from function and health toward loss of function, adverse health conditions or disability. It is recommended, then, that future research focus on understanding these mechanisms and identifying potential targets for development of new therapeutic approaches.

11. Conclusions

Conventional or standard treatment of trauma typically consists of minimizing the symptoms of the immediate, or primary, traumatic injury. With conventional or standard methods and treatments, attempts are made to minimize these immediate symptoms. Standard treatment for any persisting loss of function or disability that results from the initial trauma is typically treated by rehabilitation, which is usually initiated after there has been overt recovery from the traumatic event itself. Initiation of rehabilitation typically comes weeks or even months later, when the adverse health conditions or disability are clear and obvious.

In significant contrast, it is suggested here that in addition to standard emergency or critical care at the time of an accident or trauma specific actions be directed toward mitigating or ameliorating the sequelae of post-trauma effects that are an indirect result of a primary trauma and that are expressed as a result of the balance of restorative and degenerative processes.

Presently, there is a gap in medical care between standard practice to treat a primary injury or damage at the time of trauma, and standard practice to rehabilitate. The suggestion here is to address this gap by understanding and promoting processes that drive toward recovery and restoration of cell health and function and at the same time inhibiting processes that drive toward loss of cell function and cell death.
Significantly, the point of differentiation between conventional or standard methods and the present position is the difference between the treatment of the symptoms of the primary injury, and formulations, methods and procedures taken at or about the time of trauma to prevent or lessen damage from the secondary sequelae that may or are likely to occur.

The cascades of mechanisms leading to secondary injury are triggered within minutes to hours, yet continue to occur over the ensuing days and weeks. As a result, symptoms of secondary injury manifest over such periods, and the present position argues to reduce or prevent the manifestation or expression of these symptoms of secondary injury, which are known on the basis of incidence studies to occur.

There is a general acceptance that disability results from trauma. Incidence studies indicate that a certain number of people in a population will go on to develop disability following trauma of any given type. Medical attention has not typically been directed at reducing these numbers, or preventing them altogether. Instead, it tends to be directed at saving life and addressing the immediate condition and symptoms. Yet, much of the disability that ensues as a result of trauma is brought about by secondary injury processes, largely biochemical, which can be modified by appropriate pharmaceutical intervention. Trauma-induced disability can thus be considered an unaddressed medical need. The present position here is that the number of people who go on to develop disability following trauma can be reduced. Further, the severity of disability of those that develop a disability can be reduced. The scope and the spirit of the present overview are directed toward this unaddressed need, both by reducing the number of victims of trauma that go on to develop adverse health conditions and disability, as well as by reducing the severity of disability in those who are left with trauma-induced health conditions.

Author details

James L. Henry*

Address all correspondence to: james.henry@sapnalifesciences.ca

Sapna Life Sciences Corp. 132 North Shore Blvd. East, Burlington ON L7T 1W4, Canada

The author declares no conflict of interest.

References

[1] Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 7:281-289, 2006.
[2] Ciaramitaro P, Mondelli M, Logullo F, Grimaldi S, Battiston B, Sard A, Scarinzi C, Migliaretti G, Faccani G, Cocito D. Traumatic peripheral nerve injuries: epidemiological findings, neuropathic pain and quality of life in 158 patients. J Periph Nerv Syst 15:120-127, 2010.

[3] Mailis A, Umana M, Feindel CM. Anterior intercostal nerve damage after coronary artery bypass graft surgery with use of internal thoracic artery graft. Ann Thorac Surg. 69: 1455-1458, 2000.

[4] Macrae WA. Chronic post-surgical pain: 10 years on. Br J Anaesthes 101: 77-86, 2008.

[5] Meyerson J, Thelin S, Gordh T, Karisten R. The incidence of chronic post-sternotomy pain after cardiac surgery-a prospective study. Acta Anaesthesiol Scand 45: 940-944, 2001.

[6] Brandsborg B, Nikolajsen L, Kehlet J, Jensen TS. Chronic pain after hysterectomy. Acta Anaesthesiol Scand 52: 327-331, 2008.

[7] Kainu JP, Sarvela J, Tiippana E, Halmesmaki E, Korttila KT. Persistent pain after caesarean section and vaginal birth: a cohort study. Int J Obstetric Anes 19: 4-9, 2010.

[8] Nikolajsen L, Sorensen JC, Jensen TS, Kehlet H. Chronic pain following caesarean section. Acta Anaesthesiol Scand 48: 111-118, 2004.

[9] Bennett MI, Rayment C, Hjermstad M, Aass N, Caraceni A, Kaasa S. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain 153: 359-365, 2012.

[10] Kanbayashi Y, Hosokawa T, Okamoto K, Konishi H, Otsuji E, Yoshikawa T, Takagi T, Taniwaki M. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anticancer Drugs. 21:877-881, 2010.

[11] Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Hausheer FH. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Support Care Cancer. 17: 1071-1080, 2009.

[12] Weimer LH, Sachdev N. Update on medication-induced peripheral neuropathy. Curr Neurol Neurosci Reports 9: 69-75, 2009.

[13] Davenport JG, Farrell DF, Sumi M. "Giant axonal neuropathy" caused by industrial chemicals: neurofilamentous axonal masses in man. Neurol 26: 919-923, 1976.

[14] Borgens RB, Liu-Snyder P. Understanding secondary injury. Quart Rev Biol 87L 89-127, 2012.

[15] Vink R, Nimmo AJ. Multifunctional drugs for head injury. Neurotherapeut 6: 28-42, 2009.
[16] Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, Coderre T, Morley-Forster PK, Stinson J, Boulanger A, Peng P, Finley GA, Taenzer P, Squire P, Dion D, Cholkan A, Gilani A, Gordon A, Henry J, Jovey R, Lynch M, Mailis-Gagnon A, Panju A, Rollman GB, Velly A. Pharmacological management of chronic neuropathic pain – consensus statement and guidelines from the Canadian Pain Society. Pain Res Manage 12: 13-21, 2007.

[17] Kaas JH, Collins CE. Anatomic and functional reorganization of somatosensory cortex in mature primates after peripheral nerve and spinal cord injury. Adv Neurol 93: 8-95, 2003.

[18] Costigan M, Scholz, J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Ann Rev Neurosci 32: 1-32, 2009.

[19] Finnerup NB, Sindrup SH, Jensen TS. Chronic neuropathic pain: mechanisms, drug targets and measurement. Fund Clin Pharmacol 21: 129-136, 2007.

[20] Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmiikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132:237–251, 2007.

[21] Gilron I, Watson PN, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. Can Med Assoc J 175: 265-275, 2006.

[22] Vorobeychik Y, Gordin V, Mao J, Chen L. Combination therapy for neuropathic pain. A review of current evidence. CNS Drugs 25: 1023-1034, 2011.

[23] Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet 367: 1618–1625, 2006.

[24] Watson CP, Oaklander AL. Postherpetic neuralgia. Pain Pract 2: 295-307, 2002.

[25] Opstelten W, McElhaney J, Weinberger B, Oaklander AL, Johnson RW. The impact of varicella zoster virus: chronic pain. J Clin Virol 48 Suppl 1: S8-S13, 2010.

[26] Lapolla W, Digiorgio C, Haitz K, Magel G, Mendoza N, Grady J, Lu W, Tyring S., Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. Arch Dermatol 147: 901-907, 2011.

[27] Devor M. Ectopic discharge in Aβ afferents as a source of neuropathic pain. Exp. Brain Res. 196: 115-128, 2009.

[28] Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 288: 1765-1769, 2000.

[29] Torebjörk E. Human microneurography and intraneural microstimulation in the study of neuropathic pain. Muscle Nerve. 16: 1063-1065, 1993.
[30] Ørstavik K, Weidner C, Schmidt R, Schmelz M, Hilliges M, Jørum E, Handwerker H, Torebjörk E. Pathological C-fibres in patients with a chronic painful condition. Brain. 126: 567-578, 2003.

[31] Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33, 87-107, 1988.

[32] Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43: 205-218, 1992.

[33] Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50: 355-363, 1992.

[34] Mosconi T, Kruger L. Fixed-diameter polyethylene cuffs applied to the rat sciatic nerve induce a painful neuropathy: ultrastructural morphometric analysis of axonal alterations. Pain 64: 37-57, 1996.

[35] Malmberg AB, Basbaum AI. Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain 76: 215-222, 1998.

[36] Sung B, Na HS, Kim YI, Yoon YW, Han HC, Nahm SH, Hong SK. Supraspinal involvement in the production of mechanical allodynia by spinal nerve injury in rats. Neurosci Lett 246: 117-119, 1998.

[37] Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87: 149-158, 2000.

[38] Lee BH, Won R, Baik EJ, Lee SH, Moon CH. An animal model of neuropathic pain employing injury to the sciatic nerve branches. Neuroreport 11: 657-661, 2000.

[39] Vadakkan KI, Jia YH, Zhuo M. A behavioral model of neuropathic pain induced by ligation of the common peroneal nerve in mice. J Pain 6: 747-756, 2005.

[40] Malcangio M, Ramer MS, Jones MG, McMahon SB. Abnormal substance P release from the spinal cord following injury to primary sensory neurons. Eur. J. Neurosci. 12: 397-399, 2000.

[41] Gardell LR, Vanderah TW, Gardell SE, Wang R, Ossipov MH, Lai J, Porreca F. Enhanced evoked excitatory transmitter release in experimental neuropathy requires descending facilitation. J. Neurosci. 23: 8370-8379, 2003.

[42] Katz EJ, Gold MS. Inflammatory hyperalgesia: a role for the C-fiber sensory neuron cell body? J Pain. 7: 170-178, 2006.

[43] Pitcher GM, Henry JL. Nociceptive response to innocuous mechanical stimulation is mediated via myelinated afferents and NK-1 receptor activation in a rat model of neuropathic pain. Exp. Neurol. 186: 173-197, 2004.

[44] Amaya F, Wang H, Costigan M, Allchorne AJ, Hatcher JP, Egerton J, Stean T, Morrisset V, Grose D, Gunthorpe MJ, Chessell IP, Tate S, Green PJ, Woolf CJ. The voltage-
gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. J. Neurosci. 26: 12852-12860, 2006.

[45] Noguchi K, Kawai Y, Fukuoka T, Senba E, Miki K. Substance P induced by peripheral nerve injury in primary afferent sensory neurons and its effect on dorsal column nucleus neurons. J Neurosci 15: 7633-7643, 1995.

[46] Hofmann HA, De VJ, Siegling A, Spreyer P, Denzer D. Pharmacological sensitivity and gene expression analysis of the tibial nerve injury model of neuropathic pain. Eur. J. Pharmacol. 470: 17-25, 2003.

[47] Yang RH, Xing JL, Duan JH, Hu SJ. Effects of gabapentin on spontaneous discharges and subthreshold membrane potential oscillation of type A neurons in injured DRG. Pain 116: 187-193, 2005.

[48] Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol. Sci. 28: 75-82, 2007.

[49] Fink K, Meder W, Dooley DJ, Gothert M. Inhibition of neuronal Ca(2+) influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br. J. Pharmacol. 130: 900-906, 2000.

[50] Campbell JN, Raja SN, Meyer RA, Mackinnon SE. Myelinated afferents signal the hyperalgesia associated with nerve injury. Pain 32: 89-94, 1988.

[51] Han HC, Lee DH, Chung JM. Characteristics of ectopic discharges in a rat neuropathic pain model. Pain 84: 253-261, 2000.

[52] Liu CN, Wall PD, Ben-Dor E, Michaelis M, Amir R, Devor M. Tactile allodynia in the absence of C-fiber activation: altered firing properties of DRG neurons following spinal nerve injury. Pain 85: 503-521, 2000.

[53] Tal M, Wall PD, Devor M. Myelinated afferent fiber types that become spontaneously active and mechanosensitive following nerve transection in the rat. Brain Res. 824: 218-223, 1999.

[54] Zhu YF, Wu Q, Henry JL. Changes in functional properties of A-type but not C-type sensory neurons in vivo in a rat model of peripheral neuropathy. J Pain Res 5:175-192, 2012.

[55] Wong J, Oblinger MM. A comparison of peripheral and central axotomy effects on neurofilament and tubulin gene expression in rat dorsal root ganglion neurons. J Neurosci 10: 2215-2222, 1990.

[56] Whiteside G, Doyle CA, Hunt SP, Munglani R. Differential time course of neuronal and glial apoptosis in neonatal rat dorsal root ganglia after sciatic nerve axotomy. Wur J Neurosci 10: 3400-3408, 1998.

[57] George FB, Glass JD, Griffin JW. Axotomy-induced axonal degeneration is mediated by calcium influx through ion-specific channels. J Neurosci 15: 6445-6452, 1995.
[58] Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron 52: 77-92, 2006.

[59] Blumberg H, Janig W. Changes in unmyelinated fibers including sympathetic postganglionic fibers of a skin nerve after peripheral neuroma formation. J Auton Nerv Syst 6: 173-183, 1982.

[60] Gillatt RW, Jhorth RJ. Nerve conduction during Wallerian degeneration in the baboon. J Neurol Neurosurg Psychiat 35: 335-341, 1972.

[61] Chaudhry V, Cornblath DR. Wallerian degeneration in human nerves: serial electrophysiological studies. Muscle Nerve 15: 687-693, 1992.

[62] Tandrup T, Woolf CJ, Coggeshall RE. Delayed loss of small dorsal root ganglion cells after transection of the rat sciatic nerve. J Comp Neurol 26: 172-180, 2006.

[63] Woolf CJ, Shortland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature 355: 75-78, 1992.

[64] Kim D, Figueroa KW, Li K-W, Boroujerdi A, Yolo, T, Luo ZD. Profiling of dynamically changed gene expression in dorsal root ganglia post peripheral nerve injury and a critical role of injury-induced glial fibrillary acetic protein in maintenance of pain behaviors. Pain 143: 114-122, 2009.

[65] Gold MS, Weinreich D, Kim C-S, Wang R, Treanor J, Porreca F, Lai J. Redistribution of NaV1.8 in uninjured axons enables neuropathic pain. J Neurosci 23: 158-166, 2003.

[66] Fukuoka T, Kondo E, Dai Y, Hashimoto N, Noguchi K. Brain-derived neurotrophic factor increases in the uninjured dorsal root ganglion neurons in selective spinal nerve ligation model. J Neurosci 21: 4891-5900, 2001.

[67] Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, Yaksh TL. Upregulation of dorsal root ganglion α2δ calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 15: 1868-1875, 2001.

[68] Bauer CS, Rahman W, Tran-van-Minh A, Lujan R, Dickenson AH, Dolphin AC. The anti-allodynic α2δ ligand pregabalin inhibits the trafficking of the calcium channel α2δ-1subunit to presynaptic terminals in vivo. Biochem Soc Trans. 2010 Apr; 38[2]: 525-528, 2010.

[69] Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg. 105:1805-1815, 2007.

[70] Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin-calcium channel alpha2-delta (Cavalpha2-delta) ligands Pain 142: 13-16, 2009.

[71] Stoll G, Jander S. Myers RR. Degeneration and regeneration of the peripheral nervous system: from Augustus Waller's observations to neuroinflammation. J Perip Nerv Syst 7: 13-27, 2002.
[72] Kleopa KA, Orthmann-Murphy J, Sargiannidou I. Gap junction disorders of myelinating cells. Rev Neurosci. 21: 397-419, 2010.

[73] Nualart-Marti A, Solsona C, Fields RD. Gap junction communication in myelinating glia. Biochim Biophys Acta. 1828: 69-78, 2013.

[74] Talukder RK, Sutradhar SR, Rahman KM, Uddin MJ, Akhter H. Guillain Barre syndrome. Mymensing Med J. 20:748-56, 2011.

[75] Boivin A, Pineau I, Barrette B, Filali M, Vallières N, Rivest S, Lacroix S. Toll-like receptor signaling is critical for Wallerian degeneration and functional recovery after peripheral nerve injury. J Neurosci 27: 12565-12576, 2007.

[76] Goethais S, Ydens E, Timmerman V, Janssens S. Toll-like receptor expression in the peripheral nerve. Glia 58: 1701-1709, 2010.

[77] Wu Q, Henry JL. Toll-like Receptors: at the intersection of osteoarthritis pathology and pain. In: Principles of Osteoarthritis 1. Ed Rothschild BM. InTech. (ISBN 979-953-307-082-6) pp. 429-444, 2012.

[78] Hu P, McLachlan EM. Macrophage and lymphocyte invasion of dorsal root ganglia after peripheral nerve lesions in the rat. Neuroscience 112: 23-38, 2002.

[79] Obata K, Noguchi K. BDNF in sensory neurons and chronic pain. Neurosci Res 55: 1-10, 2006.

[80] Merighi A, Bardoni R, Salio C, Lossi L, Ferrini F, Prandini M, Zonta M, Gustincich S, Carmignoto G. Presynaptic functional trkB receptors mediate the release of excitatory neurotransmitters from primary afferent terminals in lamina II (substantia gelatinosa) of postnatal rat spinal cord. Dev Neurobiol. 68: 457-475, 2008.

[81] Wilson-Gerwing TD, Stucky CL, McComb GW, Verge VMK. Neurotrophin-3 significantly reduces sodium channel expression linked to neuropathic pain states. Exp Neurol 213: 303-314, 2008.

[82] Quintao NL, Santos AR, Campos MM, Calixto JB. The role of neurotrophic factors in genesis and maintenance of mechanical hypernociception after brachial plexus avulsion in mice. Pain 136: 125-133, 2008.

[83] Shamash S, Reighert F, Rotshenker S. The cytokine network of Wallerian degeneration: tumor necrosis factor-alpha, interleukin-1 alpha, and interleukin-1 beta. J Neurosci 22: 3052-3060, 2002.

[84] Schafers MM, Gets C, Svensson CI, Luo ZD, Sommer C. Selective increase of tumour necrosis factor-alpha in injured and spared myelinated primary afferents after chronic constrictive injury of rat sciatic nerve. Eur J Neurosci 17: 791-804, 2003.

[85] Jeon SM, Lee KM, Cho JH. Expression of monocyte chemoattractant protein-1 in rat dorsal root ganglia and spinal cord in experimental models of neuropathic pain. Brain Res 1251: 103-111, 2009.
[86] Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nature Rev Neurosci 6: 521-532, 2005.

[87] Sheth RN, Dorsi MJ, Li Y, Murinson BB, Belzberg AJ, Griffin JW, Meyer RA. Mechanical hyperalgesia after an L5 ventral rhizotomy or an L5 ganglionectomy in the rat. Pain 96: 63-72, 2002.

[88] Zhang JM, Li H, Liu B, Brull SJ. Acute topical application of tumor necrosis factor alpha evokes protein kinase A-dependent responses in rat sensory neurons. J Neurophysiol 88: 1387-1392, 2002.

[89] Oh SB, Cho C, Miller RJ. Electrophysiological analysis of neuronal chemokine receptors. Methods 29: 335-344, 2003.

[90] Sun JH, Yang B, Donnelly DF, Ma C, LaMotte RH. MCP-1 enhances excitability of nociceptive neurons in chronically compressed dorsal root ganglia. J Neurophysiol 96: 2189-2199, 2006.

[91] Arvidson B. Distribution of intravenously injected protein tracers in peripheral ganglia of adult mice. Exp Neurol 63: 388-410, 1979.

[92] Seybold VS, Colcou LG, Groth RD, Mermelstein PG. Substance P initiates NFAT-dependent gene expression in spinal neurons. J Neurochem 97: 397-407, 2006.

[93] Moore KA, Kohno T, Karchewski LA, Scholz J, Baba H, Woolf CJ. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J. Neurosci. 22: 6724-6731, 2002.

[94] Coull JA, Boudreau D, Bachand K, Prescott SA, Nault F, Sik A, De Koninck P, De Koninck Y. Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature 424: 938-942, 2003.

[95] Sandkuhler J, Liu X. Induction of long-term potentiation at spinal synapses by noxious stimulation or nerve injury. Eur. J. Neurosci. 10: 2476-2480, 1998.

[96] Carlson JD, Maire JJ, Martenson ME, Heinricher MM. Sensitization of pain-modulating neurons in the rostral ventromedial medulla after peripheral nerve injury. J. Neurosci. 27: 13222-13231, 2007.

[97] Gardell LR, Vanderah TW, Gardell SE, Wang R, Ossipov MH, Lai J, Porreca F. Enhanced evoked excitatory transmitter release in experimental neuropathy requires descending facilitation. J. Neurosci. 23: 8370-8379, 2003.

[98] Porreca F, Burgess SE, Gardell LR, Vanderah TW, Malan TP, Ossipov MH, Lappi DA, Lai J. Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the mu-opioid receptor. J. Neurosci. 21: 5281-5288, 2001.

[99] Saade NE, Al AH, Abdel BS, Safieh-Garabedian B, Atweh SF, Jabbur SJ. Transient attenuation of neuropathic manifestations in rats following lesion or reversible block of the lateral thalamic somatosensory nuclei. Exp. Neurol. 197: 157-166, 2006a.
[100] Saade NE, Al AH, Chalouhi S, Baki SA, Jabbur SJ, Atweh SF. Spinal pathways involved in supraspinal modulation of neuropathic manifestations in rats. Pain 126: 280-293, 2006b.

[101] Suzuki R, Rahman W, Hunt SP, Dickenson AH. Descending facilitatory control of mechanically evoked responses is enhanced in deep dorsal horn neurones following peripheral nerve injury. Brain Res. 1019: 68-76, 2004.

[102] Pitcher GM, Henry JL. Cellular mechanisms of hyperalgesia and spontaneous pain in a spinalized rat model of peripheral neuropathy: changes in myelinated afferent inputs implicated. Eur. J. Neurosci. 12: 2006-2020, 2000.

[103] Wei F, Vadakkan KI, Toyoda H, Wu LJ, Zhao MG, Xu H, Shum FW, Jia YH, Zhuo M. Calcium calmodulin-stimulated adenylyl cyclases contribute to activation of extracellular signal-regulated kinase in spinal dorsal horn neurons in adult rats and mice. J Neurosci 26: 851-861, 2006.

[104] Prescott SA, Sejnowski TJ, De Koninck Y. Reduction of anion reversal potential subverts the inhibitory control of firing rate in spinal lamina I neurons: towards a biophysical basis for neuropathic pain. Mol Pain. 2:32, 2006.

[105] Coull JA, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, Gravel C, Salter MW, De Koninck Y. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature. 438: 1017-1021, 2005.

[106] Scholz J, Broom DC, Youn DH, Mills CD, Kohno T, Suter MR, Moore KA, Decosterd I, Coggeshall RE, Woolf CJ. Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury. J Neurosci. 25: 7317-7323, 2005.

[107] Sotgiu ML, Biella G. Contribution of central sensitization to the pain-related abnormal activity in neuropathic rats. Somatosens Mot Res. 17: 32-38, 2000.

[108] Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 152: S2-S15, 2011.

[109] Ikeda H, Kiritoshi T, Murase K. Synaptic plasticity in the spinal dorsal horn. Neurosci Res 64: 133-136, 2009.

[110] Lang PM, Schober GM, Rolke R, Wagner S, Hilge R, Offenbächer M, Treede RD, Hoffmann U, Irnich D. Sensory neuropathy and signs of central sensitization in patients with peripheral arterial disease. Pain 124: 190-200, 2006.

[111] Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 302:1985–1992, 2009.

[112] Katz J, Seltzer Z. Transition from acute to chronic postsurgical pain: risk factors and protective factors. Expert Rev Neurotherap 9:723–744, 2009.
[113] Katz J, Clarke H. Preventive analgesia and beyond: Current status, evidence, and future directions, Clinical Pain Management: Acute Pain, 2nd edition. Edited by McIntyre PE, Rowbotham DJ, Howard R. London, Hodder Arnold Ltd, pp 154–98, 2008.

[114] Brennan TJ, Kehlet H. Preventive analgesia to reduce wound hyperalgesia and persistent postsurgical pain. Anesthesiology 103:681–683, 2005.

[115] Raja SN, Dougherty PM. Reversing tissue injury-induced plastic changes in the spinal cord: the search for the magic bullet. Reg Anesth Pain Med 25:441-444, 2000.

[116] Reuben SS, Buvanendran A. Preventing the development of chronic pain after orthopaedic surgery with preventive multimodal analgesic techniques. J Bone Joint Surg Am 89: 1343-1348, 2007.

[117] Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain Ann Neurol 64: 274-283, 2008.

[118] Jabbari B, Machado D. Treatment of refractory pain with botulinum toxins-an evidence-based review. Pain Med 12: 1594-1606, 2011.

[119] Mobbs RJ, Nair S, Blum P. Peripheral nerve stimulation for the treatment of chronic pain. J Clin Neurosci 14:216–221, 2007.

[120] Kent M, Upp J, Spevak C, Shannon C, Buckenmaier C. Ultrasound-guided peripheral nerve stimulator placement in two soldiers with acute battlefield neuropathic pain. Anesth Analg, 2012.

[121] Miyazaki Y, Koike H, Akane A, Shibata Y, Nishiwaki K, Sobue G. Spinal cord stimulation markedly ameliorated refractory neuropathic pain in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid. 18:87-90, 2011.

[122] Franchi S, Valsecchi AE, Borsani E, Procacci P, Ferrari D, Zalfa C, Sartori P, Rodella LF, Vescovi A, Maione S, Rossi F, Sacerdote P, Colleoni M, Panerai AE. Intravenous neural stem cells abolish nociceptive hypersensitivity and trigger nerve regeneration in experimental neuropathy. Pain 153: 850-861, 2012.

[123] Kuner R. Central mechanisms of pathological pain. Nature Med 16: 1258-1266, 2010.

[124] Ruscheweyh R, Wilder-Smith O, Dridla R, Liu XG, Sandkühler J. Long-term potentiation in spinal nociceptive pathways as a novel target for pain therapy. Mol Pain 7:20, 2011.

[125] Zhuo M, Wu G, Wu LJ. Neuronal and microglial mechanisms of neuropathic pain. Mol Pain 4:32, 2011.

[126] Finnerup NB, Otto M, McQuay JH, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118: 289-305, 2005.

[127] Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci 26: 696-705, 2003.
[128] Chao PK, Lu KT, Lee YL, Chen JC, Wang HL, Yang YL, Cheng MY, Liao MF, Ro LS. Early systemic granulocyte-colony stimulating factor treatment attenuates neuropathic pain after peripheral nerve injury. PLoS One. 7[8]:e43680, 2012.

[129] Dableh LJ, Henry JL. Progesterone prevents development of a rat model of neuropathic pain: timing and duration of treatment are critical. J Pain Research 4: 91-101, 2011.

[130] Dableh LJ, Yashpal K, Henry JL. Neuropathic pain as a process: reversal of chronification in an animal model. J Pain Research 4: 315-323, 2011.

[131] Jeon Y, Kim CE, Jung D, Kwak K, Park S, Lim D, Kim S, Baek W. Curcumin could prevent the development of chronic neuropathic pain in rats with peripheral nerve injury. Curr Ther Res Clin Exp. 74: 1-4, 2013.

[132] Mercer SJ, Chavan S, Tong JL, Connor DJ, de Mello WF. The early detection and management of neuropathic pain following combat injury. J R Army Med Corps 155:94–98, 2009.
